Skip to main content
. 2024 Jan 11;12(1):158. doi: 10.3390/biomedicines12010158

Figure 4.

Figure 4

Clinical response and clinical and endoscopic remission outcomes among proton pump inhibitor users and non-users during vedolizumab therapy in Crohn’s disease and ulcerative colitis: (a,b) clinical response in CD and UC groups with and without the use of PPI; (c,d) clinical remission in CD and UC groups with and without the use of PPI; (e,f) endoscopic remission in CD and UC groups with and without the use of PPI; black bar: patients without PPI; grey bar: patients with PPI.